IgA nephropathy and oxidative stress: News on clinically evaluated biomarkers hits the stage

International Urology and Nephrology

Volumn 44, Issue 4, 2012, Pages 1277-1280

  Zhu, Cheng ^a   Mertens, Peter R ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; AUTOANTIBODY; BIOLOGICAL MARKER; GALACTOSE; IMMUNOGLOBULIN A1; SERUM ALBUMIN;

ARTICLE; CARBOHYDRATE ANALYSIS; COMPLEX FORMATION; ESTIMATED GLOMERULUS FILTRATION RATE; GLOMERULUS FILTRATION RATE; GLYCOSYLATION; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; MOLECULAR PATHOLOGY; OXIDATIVE STRESS; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN FUNCTION;

ANTIBODIES, ANTI-IDIOTYPIC; BIOLOGICAL MARKERS; GLOMERULONEPHRITIS, IGA; HUMANS; OXIDATIVE STRESS; SEVERITY OF ILLNESS INDEX;

EID: 84867901389     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-012-0201-5     Document Type: Article

References (37)

1. Suzuki H et al (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22(10):1795-1803
2. Mestecky J et al (2007) IgA nephropathy: current views of immune complex formation. Contrib Nephrol 157:56-63
3. Moldoveanu Z et al (2007) Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 71(11):1148-1154
4. Coppo R, Feehally J, Glassock RJ (2010) IgA nephropathy at two score and one. Kidney Int 77(3):181-186
5. Gharavi AG et al (2008) Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 19(5):1008-1014
6. Camilla R et al (2011) Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol 6(8):1903-1911
7. Berger J, Hinglais N (1968) Intercapillary deposits of IgA- IgG. J Urol Nephrol (Paris) 74(9):694-695
8. D'Amico G (1987) The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 64(245):709-727
9. Suzuki K et al (2003) Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 63(6):2286-2294
10. Waldherr R et al (1989) Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transpl 4(11):943-946
11. Barratt J et al (2009) Immune complex formation in IgA nephropathy: a case of the 'right' antibodies in the 'wrong' place at the 'wrong' time? Nephrol Dial Transpl 24(12): 3620-3623
12. Floege J (2011) The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches? Am J Kidney Dis 58(6):992-1004
13. Conley ME, Cooper MD, Michael AF (1980) Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest 66(6):1432-1436
14. Tomino Y et al (1981) Immunoglobulin A1 and IgA nephropathy. N Engl J Med 305(19):1159-1160
15. Russell MW et al (1986) IgA-associated renal diseases: antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli. J Clin Immunol 6(1):74-86
16. Allen AC et al (2001) Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int 60(3):969-973
17. Hiki Y et al (2001) Mass spectrometry proves under- O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 59(3):1077-1085
18. Coppo R, Amore A (2004) Aberrant glycosylation in IgA nephropathy (IgAN). Kidney Int 65(5):1544-1547
19. Novak J et al (2008) IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol 28(1):78-87
20. Tomana M et al (1999) Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 104(1):73-81
21. Mestecky J et al (2008) Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy. Kidney Blood Press Res 31(1):29-37
22. Novak J et al (2002) Interactions of human mesangial cells with IgA and IgA-containing immune complexes. Kidney Int 62(2):465-475
23. Novak J et al (2005) IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int 67(2):504-513
24. Shimozato S et al (2008) Serum under-galactosylated IgA1 is increased in Japanese patients with IgA nephropathy. Nephrol Dial Transpl 23(6):1931-1939
25. Descamps-Latscha B et al (2004) Early prediction of IgA nephropathy progression: proteinuria and AOPP are strong prognostic markers. Kidney Int 66(4):1606-1612
26. Durackova Z (2010) Some current insights into oxidative stress. Physiol Res 59(4):459-469
27. Witko-Sarsat V et al (1996) Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49(5):1304-1313
28. Witko-Sarsat V et al (1998) Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161(5):2524- 2532
29. Roberts IS et al (2009) The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 76(5):546-556
30. Moriyama, T., et al. (2012) Severity of nephrotic IgA nephropathy according to the Oxford classification. Int Urol Nephrol
31. Shi XY et al (2008) Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology 149(4):1829-1839
32. Liu SX et al (2006) Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 26(5):1156-1162
33. Zuwala-Jagiello J et al (2011) Advanced oxidation protein products and inflammatory markers in liver cirrhosis: a comparison between alcohol-related and HCV-related cirrhosis. Acta Biochim Pol 58(1):59-65
34. Wei XF et al (2009) Advanced oxidation protein products induce mesangial cell perturbation through PKC-dependent activation of NADPH oxidase. Am J Physiol Renal Physiol 296(2):F427-F437
35. Zhou LL et al (2009) Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanisms. Kidney Int 76(11): 1148-1160
36. Wen YK (2010) Comparison of prominent glomerular injury and prominent tubular injury in immunoglobulin a nephropathy. Int Urol Nephrol 42(3):753-758
37. Torres DD et al (2008) The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int 73(3): 327-333